Terms: = Lung cancer AND B2M, P61769, 567, ENSG00000166710
197 results:
1. Influence of malnutrition according to the glim criteria on the chemotherapy toxicities in patients with advanced lung cancer.
Li N; Xue D; Men K; Li L; Yang J; Jiang H; Meng Q; Zhang S
Support Care Cancer; 2024 May; 32(6):358. PubMed ID: 38750262
[TBL] [Abstract] [Full Text] [Related]
2. Tumor-associated NK cells drive MDSC-mediated tumor immune tolerance through the IL-6/STAT3 axis.
Neo SY; Tong L; Chong J; Liu Y; Jing X; Oliveira MMS; Chen Y; Chen Z; Lee K; Burduli N; Chen X; Gao J; Ma R; Lim JP; Huo J; Xu S; Alici E; Wickström SL; Haglund F; Hartman J; Wagner AK; Cao Y; Kiessling R; Lam KP; Westerberg LS; Lundqvist A
Sci Transl Med; 2024 May; 16(747):eadi2952. PubMed ID: 38748775
[TBL] [Abstract] [Full Text] [Related]
3. Characteristics and influencing factors of demoralization in patients with lung cancer: A latent class analysis.
Hong YT; Ye BQ; Lin JL; Chen QH; Zhang J; Chen WT; Huang FF
Psychooncology; 2024 Mar; 33(3):e6312. PubMed ID: 38429989
[TBL] [Abstract] [Full Text] [Related]
4. Differentially Expressed Genes Involved in Primary Resistance to Immunotherapy in Patients with Advanced-Stage Pulmonary cancer.
Chinchilla-Tábora LM; Montero JC; Corchete LA; González-Morais I; Del Barco Morillo E; Olivares-Hernández A; Rodríguez González M; Sayagués JM; Ludeña MD
Int J Mol Sci; 2024 Feb; 25(4):. PubMed ID: 38396726
[TBL] [Abstract] [Full Text] [Related]
5. Machine learning analysis of pathological images to predict 1-year progression-free survival of immunotherapy in patients with small-cell lung cancer.
Shibaki R; Fujimoto D; Nozawa T; Sano A; Kitamura Y; Fukuoka J; Sato Y; Kijima T; Matsumoto H; Yokoyama T; Miura S; Hata A; Tamiya M; Taniguchi Y; Sugisaka J; Furuya N; Tanaka H; Yamamoto N; Koh Y; Akamatsu H
J Immunother Cancer; 2024 Feb; 12(2):. PubMed ID: 38360040
[TBL] [Abstract] [Full Text] [Related]
6. Genomic and Immunophenotypic Landscape of Acquired Resistance to PD-(L)1 Blockade in Non-Small-Cell lung cancer.
Ricciuti B; Lamberti G; Puchala SR; Mahadevan NR; Lin JR; Alessi JV; Chowdhury A; Li YY; Wang X; Spurr L; Pecci F; Di Federico A; Venkatraman D; Barrichello AP; Gandhi M; Vaz VR; Pangilinan AJ; Haradon D; Lee E; Gupta H; Pfaff KL; Welsh EL; Nishino M; Cherniack AD; Johnson BE; Weirather JL; Dryg ID; Rodig SJ; Sholl LM; Sorger P; Santagata S; Umeton R; Awad MM
J Clin Oncol; 2024 Apr; 42(11):1311-1321. PubMed ID: 38207230
[TBL] [Abstract] [Full Text] [Related]
7. Med23 deficiency reprograms the tumor microenvironment to promote lung tumorigenesis.
Fu X; Liu S; Cao D; Li C; Ji H; Wang G
Br J Cancer; 2024 Mar; 130(5):716-727. PubMed ID: 38195889
[TBL] [Abstract] [Full Text] [Related]
8. Downregulated circ_0001681 Predicts the Occurrence and Malignant Development of lung Carcinoma via Negatively Modulating miR-567.
Li M; Mao C; Li W; Xia W; Li K; Xu R
Ann Clin Lab Sci; 2023 Nov; 53(6):881-889. PubMed ID: 38182148
[TBL] [Abstract] [Full Text] [Related]
9. Genome-wide association study meta-analysis of dizygotic twinning illuminates genetic regulation of female fecundity.
Mbarek H; Gordon SD; Duffy DL; Hubers N; Mortlock S; Beck JJ; Hottenga JJ; Pool R; Dolan CV; Actkins KV; Gerring ZF; Van Dongen J; Ehli EA; Iacono WG; Mcgue M; Chasman DI; Gallagher CS; Schilit SLP; Morton CC; Paré G; Willemsen G; Whiteman DC; Olsen CM; Derom C; Vlietinck R; Gudbjartsson D; Cannon-Albright L; Krapohl E; Plomin R; Magnusson PKE; Pedersen NL; Hysi P; Mangino M; Spector TD; Palviainen T; Milaneschi Y; Penninnx BW; Campos AI; Ong KK; Perry JRB; Lambalk CB; Kaprio J; Ólafsson Í; Duroure K; Revenu C; Rentería ME; Yengo L; Davis L; Derks EM; Medland SE; Stefansson H; Stefansson K; Del Bene F; Reversade B; Montgomery GW; Boomsma DI; Martin NG
Hum Reprod; 2024 Jan; 39(1):240-257. PubMed ID: 38052102
[TBL] [Abstract] [Full Text] [Related]
10. Enhanced Patient Comfort and Satisfaction with Early Oral Feeding after Thoracoscopic lung cancer Resection.
Wu Y; Liu H; Zhong M; Chen X; Ba Z; Qiao G; Feng J; Zeng X
Med Sci Monit; 2023 Nov; 29():e941577. PubMed ID: 37953532
[TBL] [Abstract] [Full Text] [Related]
11. A 20-year Follow-up of the International Early lung cancer Action Program (I-ELCAP).
Henschke CI; Yip R; Shaham D; Markowitz S; Cervera Deval J; Zulueta JJ; Seijo LM; Aylesworth C; Klingler K; Andaz S; Chin C; Smith JP; Taioli E; Altorki N; Flores RM; Yankelevitz DF;
Radiology; 2023 Nov; 309(2):e231988. PubMed ID: 37934099
[TBL] [Abstract] [Full Text] [Related]
12. Transcriptome-level discovery of survival-associated biomarkers and therapy targets in non-small-cell lung cancer.
Győrffy B
Br J Pharmacol; 2024 Feb; 181(3):362-374. PubMed ID: 37783508
[TBL] [Abstract] [Full Text] [Related]
13. Potential Association of Cytochrome P450 Copy Number Alteration in Tumour with Chemotherapy Resistance in lung Adenocarcinoma Patients.
Incze E; Mangó K; Fekete F; Kiss ÁF; Póti Á; Harkó T; Moldvay J; Szüts D; Monostory K
Int J Mol Sci; 2023 Aug; 24(17):. PubMed ID: 37686184
[TBL] [Abstract] [Full Text] [Related]
14. Cell Surface b2m-Free Human Leukocyte Antigen (HLA) Monomers and Dimers: Are They Neo-HLA Class and Proto-HLA?
Ravindranath MH; Ravindranath NM; Selvan SR; Hilali FE; Amato-Menker CJ; Filippone EJ
Biomolecules; 2023 Jul; 13(8):. PubMed ID: 37627243
[TBL] [Abstract] [Full Text] [Related]
15. Global epidemiologic patterns of oropharyngeal cancer incidence trends.
Zumsteg ZS; Luu M; Rosenberg PS; Elrod JK; Bray F; Vaccarella S; Gay C; Lu DJ; Chen MM; Chaturvedi AK; Goodman MT
J Natl Cancer Inst; 2023 Dec; 115(12):1544-1554. PubMed ID: 37603716
[TBL] [Abstract] [Full Text] [Related]
16. The effects of tislelizumab treatment on the health-related quality of life of patients with advanced non-small cell lung cancer.
Huang D; Zhou C; Barnes G; Ma Y; Li S; Zhan L; Tang B
Cancer Med; 2023 Aug; 12(16):17403-17412. PubMed ID: 37587845
[TBL] [Abstract] [Full Text] [Related]
17. Preoperative serum bilirubin is an independent prognostic factor for curatively resected esophageal squamous cell carcinoma.
Huang X; Chen Y; Yang H; Wang R; Chen Z
BMC Cancer; 2023 Jul; 23(1):706. PubMed ID: 37507653
[TBL] [Abstract] [Full Text] [Related]
18. Real-World Outcomes of Stage IV NSCLC with PD-L1 ≥ 50% Treated with First-Line Pembrolizumab: Uptake of Second-Line Systemic Therapy.
Rittberg R; Leung B; Shokoohi A; Pender A; Wong S; Al-Hashami Z; Wang Y; Ho C
Curr Oncol; 2023 May; 30(6):5299-5308. PubMed ID: 37366885
[TBL] [Abstract] [Full Text] [Related]
19. Safety and Efficacy of Immune Checkpoint Inhibitors in cancer Patients and Preexisting Autoimmune Disease: A Systematic Review and Meta-Analysis in Non-Small-Cell lung cancer.
Aung WY; Lee CS; Morales J; Rahman H; Seetharamu N
Clin Lung Cancer; 2023 Nov; 24(7):598-612. PubMed ID: 37328320
[TBL] [Abstract] [Full Text] [Related]
20. Estimating time and transportation costs associated with lung cancer screening and diagnostic lung procedures in Taiwan: a cross-sectional survey in a medical centre.
Wu CH; Ku LE; Lin CY; Chung TJ; Liu HJ; Chao TH; Yang SC
BMJ Open; 2023 Mar; 13(3):e070647. PubMed ID: 36898750
[TBL] [Abstract] [Full Text] [Related]
[Next]
